Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series-Reference-Cited by-同舟云学术

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series

Published:2018-05 Issue:4 Volume:4 Page:310-313
ISSN:2352-5126
Container-title:JAAD Case Reports
language:en
Short-container-title:JAAD Case Reports

Author:

Phung Michelle,Georgakopoulos Jorge R.,Ighani Arvin,Giroux Lyne,Yeung Jensen

Publisher

Elsevier BV

Subject

Dermatology

Reference3 articles.

1. Novartis Pharmaceuticals Canada Inc. Dorval, QC. Cosentyx (secukinumab). Available at: https://pdf.hres.ca/dpd_pm/00040683.PDF. Accessed September 6, 2017.

2. Heterogeneity of response to biologic treatment: perspective for psoriasis;Edson-Heredia;J Invest Dermatol,2013

3. Secukinumab in plaque psoriasis – results of two phase 3 trials;Langley;N Engl J Med,2014

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Guttate Psoriasis: A Systematic Review;Journal of Cutaneous Medicine and Surgery;2024-07-30

2. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry;Archives of Dermatological Research;2024-06-08

3. Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis;Clinical and Experimental Dermatology;2022-04-25

4. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study;British Journal of Dermatology;2021-12-27

5. Secukinumab efficacy in the treatment of various types of psoriasis: A case series;Adesh University Journal of Medical Sciences & Research;2021-12-15